Policy Updates   |   Position Statements

ASGCT Submits Comments on FDA Draft Guidance on Regenerative Medicine Expedited Programs

ASGCT Staff - February 19, 2018

ASGCT expressed appreciation for guidance titled, “Expedited Programs for Regenerative Medicine Therapies for Serious Conditions," especially on the Regenerative Medicine Advanced Therapy (RMAT) designation and the inclusion of certain gene therapies in the eligibility for consideration for RMAT designation.

ASGCT leadership submitted comments to the FDA last week on the draft guidance titled, “Expedited Programs for Regenerative Medicine Therapies for Serious Conditions.” ASGCT expressed appreciation for guidance on these programs, especially on the Regenerative Medicine Advanced Therapy (RMAT) designation and the inclusion of certain gene therapies in the eligibility for consideration for RMAT designation.

The guidance identifies gene therapies, including genetically modified cells, which lead to a durable modification of cells or tissues, as eligible for RMAT designation.

A primary recommendation from ASGCT is to expand the eligibility for RMAT designation to all gene therapies to encourage the development of such therapies, which hold the potential to provide treatment for significant unmet need for multiple diseases.

Share This Page

Related Articles

FDA photo

Education

Margaret Hamburg, M.D. to Speak at Policy Summit

ASGCT Staff - September 26, 2019

Credit: Daniel Soñé Photography, LLC

Education

NIH Director Collins to Speak at ASGCT Policy Summit

ASGCT Staff - September 05, 2019

NIH Director Francis Collins, M.D., Ph.D
Credit: NIH

Policy Updates

What to Expect at the ASGCT Policy Summit

ASGCT Staff - September 04, 2019

Credit: U.S. Mission Photo by Eric Bridiers, Flickr.com

Advocacy

ASGCT Submits Comments to WHO Advisory Committee

ASGCT Staff - August 22, 2019